Mammogen’s lead product candidate, genTRU-breast™, is a blood-based molecular assay designed to provide real-time biologic signal to support earlier breast cancer detection, particularly for women with dense breast tissue. The company’s platform combines proprietary RNA biomarker discovery, computational interpretation, molecular classification technology, and scalable real-time qPCR infrastructure. Mammogen’s clinical publications have emphasized detection of Stage I breast cancer, reflecting a focus on earliest actionable stages of disease. The company was founded within the IV BioHoldings (IVBH) ecosystem and intends to expand its pipeline into additional women’s health applications over time. Mammogen plans to commercialize using existing CLIA-certified laboratory infrastructure and to grow strategic relationships across the diagnostics and women’s health landscape. The Series A financing is intended to accelerate the company’s pivotal clinical program and commercialization roadmap.

Total raised

$30M

Funding rounds

1

Latest round

Series A

Latest activity

Jun 2026